Apolipoprotein B levels in adults with type 1 diabetes not receiving lipid-lowering therapy

被引:7
作者
Mazanderani, Adel B. [1 ]
Wise, Stephanie J. [1 ]
Tildesley, Hugh D. [1 ,2 ]
机构
[1] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[2] St Pauls Hosp, Dept Endocrinol & Metab, Vancouver, BC V6Z 1Y6, Canada
关键词
Apolipoprotein B; Type; 1; diabetes; Lipid-lowering targets; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; A-I; LIPOPROTEIN; RISK; DYSLIPIDEMIA; CHOLESTEROL; PREVALENCE; PREVENTION; MELLITUS;
D O I
10.1016/j.clinbiochem.2009.05.013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: To investigate apolipoprotein B (apoB) levels in adult patients with type 1 diabetes with no history of cardiovascular disease and not receiving lipid-lowering therapy. Design and methods: Subjects (n = 169) were divided into two groups based on gender. Primary analysis examined lipid parameters and glycosylated hemoglobin. Secondary analysis involved classifying patients according to the Canadian Diabetes Association's (CDA) LDL cholesterol and apoB targets. Results: Mean apoB levels were 0.81 +/- 0.17 g/L in males and 0.78 +/- 0.18 g/L in females. We also found that among patients who failed to achieve the CDA LDL cholesterol target, 46% of males and 54% of females met the apoB target. Conclusions: There is low prevalence of elevated apoB among patients with type 1 diabetes. In addition, there is discordance between the proportions of patients meeting either LDL cholesterol or apoB targets, thus a significant number of patients may be prescribed lipid-lowering medications unnecessarily. (C) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1218 / 1221
页数:4
相关论文
共 19 条
  • [1] Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes
    Albers, John J.
    Marcovina, Santica M.
    Imperatore, Giuseppina
    Snively, Beverly M.
    Stafford, Jeanette
    Fujimoto, Wilfred Y.
    Mayer-Davis, Elizabeth J.
    Petitti, Diana B.
    Pihoker, Catherine
    Dolan, Larry
    Dabelea, Dana M.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (03) : 735 - 742
  • [2] Bachorik PS, 1997, CLIN CHEM, V43, P2364
  • [3] Lipoprotein management in patients with cardiometabolic risk
    Brunzell, John D.
    Davidson, Michael
    Furberg, Curt D.
    Goldberg, Ronald B.
    Howard, Barbara V.
    Stein, James H.
    Witztum, Joseph L.
    [J]. DIABETES CARE, 2008, 31 (04) : 811 - 822
  • [4] Buse J., 2003, CLIN DIABETES, V21, P168
  • [5] *CAN DIAB ASS, 2008, CAN J DIABETES S1, V32, pS107
  • [6] Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes
    Chaturvedi, N
    Fuller, JH
    Taskinen, MR
    [J]. DIABETES CARE, 2001, 24 (12) : 2071 - 2077
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [9] A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias
    de Graaf, Jacqueline
    Couture, Patrick
    Sniderman, Allan
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11): : 608 - 618
  • [10] Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    Gotto, AM
    Whitney, E
    Stein, EA
    Shapiro, DR
    Clearfield, M
    Weis, S
    Jou, JY
    Langendörfer, A
    Beere, A
    Watson, DJ
    Downs, JR
    de Cani, JS
    [J]. CIRCULATION, 2000, 101 (05) : 477 - 484